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Background: To determine the effects of post-challenge hyperglycemia potentiate low-density lipoprotein cholesterol
(LDL) particles on the risk of arterial stiffness in non-diabetic adults.
Methods: During 2009–2011, 592 adults without clinical diabetes (fasting glucose <7.0 mmol/L) or known coronary
heart disease or stroke were recruited. All subjects underwent standard 75-g oral glucose tolerance test (OGTT) after
overnight fasting. The glucose area under curve (GluAUC) after OGTT was defined as the postchallenge glucose load.
Levels of LDL-C and small dense LDL-C (sdLDL-C) were measured. Arterial stiffness in terms of brachial–ankle pulse
wave velocity (baPWV) was also measured.
Results: The baPWV in tertile distributions were significantly associated with all conventional cardiovascular risk factors,
LDL-C, and sdLDL-C. Multivariate logistic regression analyses revealed that LDL-C (or sdLDL-C) combined with one of
the seven glycemic indices (glucose levels at 0, 30, 60, 90, and 120 min; GluAUC; HbA1C) was associated with arterial
stiffness after covariates being adjusted. Further interaction analyses showed only concurrent higher levels of
both glycemic indices and atherogenic LDL-C or sdLDL-C have significant risk for arterial stiffness.
Conclusions: Additive effects of both postchallenge hyperglycemia and LDL subclass particles potentiate the risk
of arterial stiffness. The adverse joint effects of hyperlipidemia and postchallenge hyperglycemia on subclinical
cardiovascular function provide important information in primary prevention of cardiovascular disease in subjects
without clinical diabetes.
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Several epidemiological and pathological studies have
shown that diabetes is an independent risk factor for car-
diovascular disease (CVD) in men and women [1]. As the
recommendation from the 2002 National Cholesterol
Education Program Adult Treatment Panel III, diabetes
mellitus has been considered as a coronary heart disease
(CHD) equivalent [2], although residual controversy has
continued into this decade. Recently, it was demonstrated* Correspondence: fuwaihospital@gmail.com; tachensu@ntu.edu.tw
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unless otherwise stated.that some diabetic CHD patients may be at a greater risk
of CVD morbidity and mortality compared with nondia-
betic CHD patients [3]. Moreover, the Heart Protection
Study provides direct evidence that cholesterol-lowering
therapy is beneficial for people with diabetes even if they
have not developed CHD or display elevated cholesterol
concentrations [4]. Another study also showed that
cholesterol-lowering therapy is efficacious in reducing the
risk of first CVD events in patients with type 2 diabetes
without high low-density lipoprotein (LDL) cholesterol
(LDL-C) levels [5]; however, the interaction between glu-
cose and the cholesterol concentrations remains unclear.
On the other hand, about one-third of American adults
and two-thirds of CHD patients have abnormal glu-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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uals are still within nondiabetic glucose levels (fasting
plasma glucose, FPG < 7.0 mmol/l or 2-h plasma glu-
cose <11.1 mmol/l), but show prediabetes classification
with impaired glucose tolerance (FPG <7.0 mmol/l and
2-h plasma glucose ≥7.8 and <11.1 mmol/l) or diabetes
classification after an oral glucose tolerance test (2-h
plasma glucose >11.1 mmol/l) or an ingestion of a meal.
Several studies have shown that postchallenge glucose
levels are more strongly associated with CVD compared
with fasting glucose levels [8,9], besides, glucose levels
after a glucose challenge exhibit continuous linear rela-
tionships with both CVD death and all-cause mortality
risk [10]. Alternatively, the importance of 2-h plasma glu-
cose levels during oral glucose tolerance test (OGTT) is
well established, but the importance of postchallenge
hyperglycemia remains unclear [11].
Although the above studies indicated the importance of
postprandial glucose levels, fasting plasma glucose and
glycated hemoglobin (HbA1c) levels still play important
roles in the assessment of glycemic levels, whereas post-
challenge glucose values are often neglected [12]. This
may be because of the inconvenience and cost of measur-
ing these parameters in daily clinical practice [13]. The
most common clinical phenotypes of dyslipidemia in
individuals with impaired glucose metabolism include
low high-density lipoprotein cholesterol (HDL-C) levels,
hypertriglyceridemia, and a higher ratio of small dense
LDL-cholesterol (sdLDL-C) [14-17]. Higher levels of
sdLDL particles are considered to be more atherogenic
compared with large buoyant LDL-C particles; therefore,
sdLDL-C is considered to be an important and independ-
ent predictor of CVD [18,19].
Brachial-ankle pulse wave velocity (baPWV) can be
noninvasively measured simply by wrapping the four ex-
tremities with blood pressure cuffs, and it serves as a
simple marker of vascular damage and cardiovascular
risk [20,21]. Earlier studies on experimental atheroscler-
osis in monkeys demonstrated that the aortic pulse wave
velocity (PWV) increased with the development of athero-
sclerosis [22]. The Rotterdam study, a population-based
study including more than 3,000 subjects, demonstrated a
strong association of aortic PWV with intima-media thick-
ness (IMT) and the severity of plaques as measured by
ultrasonographic tests [23]. In addition, from our previ-
ously work, which have demonstrated that postchallenge
hyperglycemic spikes correlate with arterial stiffness which
was independent of confounding factors in adults without
diabetes [24].
Thus, we propose that measuring sdLDL particle con-
centrations in a cohort study involving individuals without
clinical diabetes would be helpful in evaluating its earlier
role of dyslipidemia-glucose hypothesis in atherosclerosis;
we conducted this study among healthy adults withoutdiabetes with the aim of investigating whether postchal-
lenge hyperglycemia and LDL subclass particles exerted
additive effects on arterial stiffness.
Results
The cardiovascular characteristics of all participants were
compared according to the tertile distribution of sdLDL
levels; subjects without previously known clinical diabetes
that displayed 2-h glucose ≥11.1 mmol/l after OGTT were
considered OGTT diabetes (Table 1). A strong correlation
between different glycemic indices such as OGTT dia-
betes, GluAUC and fasting glucose across sdLDL-C tertile
(Table 1) was noted. The conventional risk factors for
CVD and diabetes, except smoking and alcohol consump-
tion, showed statistically significant differences in the
trend test across the three groups. Subjects with higher
sdLDL levels exhibited more conventional risk factor for
CVD and diabetes. Higher LDL-C and sdLDL/LDL ratios
were also noted across the higher sdLDL levels. Most con-
ventional risk factors and the novel risk factors of sdLDL
and GluAUC were significantly associated with baPWV
across the tertile distribution (Table 2). The upper tertile
of baPWV subjects associated with significantly higher
glucose profiles including OGTT diabetes, FPG, GluAUC
and HbA1C and lipid profiles such as cholesterol, trigly-
ceride, LDL-C, sdLDL-C and sdLDL-C/LDL-C ratio. In
contrast, levels of large LDL-C were borderline but signifi-
cantly associated with baPWV. Additionally, there are no
significant associations between baPWV and statin-users,
and between baPWV and renal function index of esti-
mated glomerular filtration rate.
Multivariate logistic regression models were applied to
elucidate the impact of different glycemic indices, includ-
ing post-OGTT glucose levels, GluAUC, and HbA1C,
combined with LDL-C (Table 3) or with sdLDL-C
(Table 4) on the risk of baPWV. The results demonstrated
that fasting glucose levels were not associated with arterial
stiffness after controlling for other covariates; however,
postchallenge glucose levels at 30, 60, 90, and 120 min
and GluAUC were significantly and positively associated
with arterial stiffness. Furthermore, the joint effects of
postchallenge glucose levels and GluAUC with either
LDL-C or sdLDL-C were significantly linked to arterial
stiffness. On the other hand, when the joint effects of both
LDL-C and fasting glucose levels or LDL-C and HbA1C
were considered, the two glycemic indices no longer had a
significant influence on increased baPWV (Table 3). Simi-
lar findings were observed when LDL-C was replaced with
sdLDL-C in the same multivariate models (Table 4). Fast-
ing glucose and HbA1C did not significantly influence the
risk of arterial stiffness in the initial multivariate analyses
(Tables 3 and 4).
However, further multivariate analyses using interaction
analyses between glycemic indices and atherogenic
Table 1 Cardiovascular characteristics of participants according to tertile distribution of small dense-low-density
lipoprotein cholesterol (sdLDL-C)
sdLDL-C, mmol/L
Upper Middle Lower p-value
≥ 37.7 24.0-37.7 < 24.0
Characteristics N = 197 N = 197 N = 198
Age, years 45.82 ± 7.61 44.41 ± 7.96 45.13 ± 7.99 0.390
Male, % 91.88 90.16 78.35 <.001
BMI, kg/m2 25.79 ± 2.95 25.26 ± 3.62 24.19 ± 3.19 <.001
Waist, cm 87.28 ± 7.94 85.61 ± 10.1 81.87 ± 9.04 <.001
Smoking, % 20.81 14.95 14.29 0.083
Alcohol, % 23.86 21.65 14.8 0.025
Hypertension, % 27.92 18.04 14.8 0.001
Systolic BP, mmHg 126.04 ± 14.67 121.23 ± 10.91 117.44 ± 13.23 <.001
Diastolic BP, mmHg 77.53 ± 9.79 74.18 ± 8.19 71.28 ± 9.51 <.001
OGTT diabetes, % 9.14 4.12 3.57 0.017
Fasting glucose, mmol/L 5.45 ± 1.21 5.15 ± 0.78 5.03 ± 0.93 <.001
GluAUC, mmol/L 32.53 ± 10.07 29.24 ± 7.01 26.64 ± 8.13 <.001
HbA1C, % 5.85 ± 1.05 5.55 ± 0.46 5.56 ± 0.69 <.001
Cholesterol, mmol/L 5.98 ± 0.88 5.31 ± 0.62 4.7 ± 0.65 <.001
Triglyceride, mmol/L 2.39 ± 1.49 1.48 ± 0.75 0.99 ± 0.41 <.001
HDL-C, mmol/L 1.22 ± 0.3 1.27 ± 0.31 1.37 ± 0.3 <.001
LDL-C, mmol/L 3.55 ± 0.89 3.15 ± 0.61 2.59 ± 0.52 <.001
sdLDL-C/LDL-C 0.39 ± 0.13 0.26 ± 0.07 0.18 ± 0.04 <.001
OGTT Diabetes: subjects’ results with OGTT two hour value >11.1 mmol/l.
Abbreviations: OGTT oral glucose tolerance test, GluAUC glucose area under curve after OGTT.
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concurrent with highest tertile levels of LDL-C (or
sdLDL-C) and higher half levels glycemic indices have
significant risk for arterial stiffness and this is inde-
pendent of fasting status (either fasting or postchal-
lenge) or HbA1C levels (Table 5).
Discussion
To the best of our knowledge, the present study is the
first to demonstrate the concurrent presence of both
atherogenic lipoprotein particles (LDL and sdLDL) and
postchallenge hyperglycemia as risk factors of arterial
stiffness in nondiabetic adults. The novel finding of sig-
nificant interactions between LDL subclass particles and
different glycemic indices also indicate an additive effect
between these two risk factors on arterial stiffness. In
addition to postchallenge glucose levels, both LDL-C
and sdLDL-C levels were significantly related to an in-
creased risk of arterial stiffness. Another novel result of
our study found that sdLDL-C might play an important
role as LDL-C as it being closely related to the early ath-
erosclerosis maker of baPWV.
Formerly studies have demonstrated that postchal-
lenge hyperglycemia status predisposes a higher risk ofatherosclerosis or CVD that can be attributed to the
rapid increase in oxidative stress after meals or post
glucose load [25]. Therefore, postchallenge hyperglycemia
may trigger the interaction between oxidative stress,
remnant-like lipoproteins, LDL-C, and sdLDL and subse-
quently elevate the risk of cardiovascular complications.
Our study showed that postchallenge hyperglycemia at all
the different time-course (30, 60, 90, and 120 min) and
GluAUC was strongly related to arterial stiffness; there-
fore, it is reasonable to postulated that postchallenge
hyperglycemia could have additive effects with atherogenic
lipoprotein particles (LDL and sdLDL) on subclinical ath-
erosclerosis, former research have indicated that glucose-
mediated elastic artery sclerosis may play an integral role
in the development of macrovascular complications [26].
The additive effects of atherogenic LDL-C (or sdLDL-C)
and different glycemic indices on arterial stiffness demon-
strated that postchallenge hyperglycemia have similar ef-
fects on subclinical atherogenesis compared with fasting
glucose or HbA1C, particularly in subjects with higher
sdLDL-C or LDL-C levels.
Additionally, our study also provides direct evidence
that the occurrence of hyperglycemia, which was inde-
pendent from the status of postchallenge, fasting, or
Table 2 Cardiovascular characteristics of participants according to tertile distribution of brachial–ankle pulse wave
velocity (baPWV)
baPWV
Upper Middle Lower p-value
≥ 1438.3 1322.5-1438.3 < 1322.5
Characteristics N = 198 N = 197 N = 197
Age, years 48.18 ± 7.35 45.12 ± 7.53 42.24 ± 7.58 <.001
Male, % 92.93 87.24 81.03 0.004
BMI, kg/m2 25.43 ± 3.23 25.27 ± 3.26 24.58 ± 3.48 0.010
Waist, cm 86.34 ± 8.48 85.23 ± 9.06 83.37 ± 10.17 0.001
Smoking, % 20.2 13.71 16.75 0.359
Alcohol, % 22.22 21.83 15.23 0.081
Hypertension, % 33.84 17.77 8.12 <.001
Systolic BP, mmHg 129.61 ± 14.58 121.52 ± 10.71 113.59 ± 9.25 <.001
Diastolic BP, mmHg 79.50 ± 9.71 75.02 ± 7.85 68.59 ± 7.44 <.001
OGTT diabetes, % 9.6 4.06 1.52 <.001
Fasting glucose, mmol/L 5.39 ± 0.92 5.18 ± 0.89 4.99 ± 0.86 <.001
GluAUC, mmol/L 32.38 ± 9.84 29.09 ± 7.82 27.37 ± 7.97 <.001
HbA1C, % 5.77 ± 0.87 5.62 ± 0.57 5.51 ± 0.72 <.001
Cholesterol, mmol/L 5.50 ± 0.96 5.37 ± 0.93 5.14 ± 0.74 <.001
Triglyceride, mmol/L 1.85 ± 1.43 1.61 ± 0.94 1.41 ± 0.97 <.001
HDL-C, mmol/L 1.24 ± 0.27 1.30 ± 0.32 1.33 ± 0.33 0.005
LDL-C, mmol/L 3.28 ± 0.87 3.12 ± 0.76 2.90 ± 0.71 <.001
sdLDL, mmol/L 0.96 ± 0.47 0.86 ± 0.41 0.73 ± 0.33 <.001
Large LDL-C, mmol/L 2.31 ± 0.71 2.28 ± 0.64 2.18 ± 0.60 0.037
sdLDL-C/LDL-C 0.30 ± 0.14 0.27 ± 0.12 0.25 ± 0.11 <.001
eGFR, ml/min 87.26 ± 19.60 88.91 ± 20.49 89.39 ± 20.05 0.323
Statin-users, % 13.13 8.63 9.64 0.257
OGTT Diabetes: subjects’ results with OGTT two hour value >11.1 mmol/l.
Abbreviations: OGTT oral glucose tolerance test, GluAUC glucose area under curve after OGTT, sdLDL-C small dense LDL-C, Large LDL-C = LDL-C – sdLDL-C,
eGFR estimated glomerular filtration rate.
Table 3 Multiple logistic regression analyses for the risk [odds ratios (95% confidence intervals)] of higher
brachial–ankle pulse wave velocity (baPWV ≥75th percentile) focused on the combined effects of LDL-C and different
glycemic indices
Basic modelsa Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
LDL-C 1.62(1.27-2.06)‡ 1.59(1.24-2.02)‡ 1.55(1.21-1.99)‡ 1.53(1.19-1.95)‡ 1.56(1.22-1.99)‡ 1.57(1.23-2.00)‡ 1.54(1.20-1.97)‡ 1.60(1.25-2.04)‡
Glucose,
0 min 1.24(0.99-1.55)* 1.19(0.96-1.48) — — — — — —
30 min 1.23(1.10-1.38)* — 1.21(1.08-1.35)† — — — — —
60 min 1.15(1.07-1.23)* — — 1.13(1.05-1.22)* — — — —
90 min 1.12(1.05-1.20)* — — — 1.10(1.03-1.18)* — — —
120 min 1.12(1.04-1.20)* — — — — 1.10(1.02-1.19)* — —
GluAUC 1.09(1.04-1.14)* — — — — — 1.08(1.03-1.13)* —
HbA1C 1.34(1.02-1.76)* — — — — — — 1.30(0.99-1.72)
aBasic models included LDL-C or one of the seven glycemic indices after controlling for age, male gender, BMI, hypertension, smoking, and alcohol consumption habit.
p-value: *<0.05, †<0.01, ‡<0.001.
Models 1 to 7 combined both LDL-C and one of the seven glycemic indices after controlling for age, male gender, BMI, hypertension, smoking, and alcohol consumption.
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Table 4 Multiple logistic regression analyses for the risk [odds ratios (95% confidence intervals)] of higher
brachial–ankle pulse wave velocity (baPWV ≥75th percentile) focused on the combined effects of sdLDL-C and different
glycemic indices
Basic modelsa Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
sdLDL-C 2.51(1.56-4.05)‡ 2.38(1.46-3.87)‡ 2.17(1.32-3.57)‡ 2.12(1.29-3.48)‡ 2.22(1.36-3.64)‡ 2.30(1.42-3.75)‡ 2.16(1.31-3.54)‡ 2.37(1.46-3.86)‡
Glucose,
0 min 1.24(0.99-1.54) 1.15(0.93-1.43) — — — — — —
30 min 1.23(1.10-1.38)† — 1.18(1.05-1.33)† — — — — —
60 min 1.15(1.07-1.23)* — — 1.12(1.04-1.20)* — — — —
90 min 1.12(1.04-1.20)* — — — 1.09(1.02-1.17)* — — —
120 min 1.11(1.03-1.20)* — — — — 1.09(1.01-1.18)* — —
GluAUC 1.09(1.04-1.14)* — — — — — 1.07(1.02-1.12)* —
HbA1C 1.36(1.02-1.75)* — — — — — — 1.22(0.93-1.60)
aBasic models included sdLDL-C or one of the seven glycemic indices after controlling for age, male gender, BMI, hypertension, smoking, and alcohol consumption habit.
p-value: *<0.05, †<0.01, ‡<0.001.
Models 1 to 7 combined both sdLDL-C and one of the seven glycemic indices after controlling for age, male gender, BMI, hypertension, smoking, and alcohol consumption.
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protein particles (LDL and sdLDL) on the risk of sub-
clinical atherosclerosis. The findings may also further
support the results of elegant large-scale lipid-lowering
trials among diabetes that demonstrate that with statin
treatments can significantly slowing atherogenic pro-
gress. Thus, may contribute the reduction of cardiovas-
cular morbidity and mortality risk [27].
Moreover, our results also are in agreement with those
previous studies reported that an increase in sdLDL par-
ticles and increased postchallenge hyperglycemia may
lead to an elevated risk of subclinical CVD [28,29]. Also,
based on LDL particle size has been found to be the
strongest marker of clinically apparent and nonapparent
atherosclerosis in patients with type 2 diabetes [30].
These studies further displayed that quantitative sdLDL-
C measurements could provide alternative useful infor-
mation for the risk assessment of atherosclerotic disease
in addition to LDL-C [31].Table 5 Multivariate logistic regression analyses for the inter
(GI) on the risk of arterial stiffness (baPWV ≥75th percentile)
AC Glucose 30 Glucose 6
LDL-C ≥2/3 & GI ≥50% 2.63(1.59,4.35)‡ 2.13(1.29,3.52)† 2.26(1.36,3.7
LDL-C ≥2/3 & GI <50% 1.69(0.99,2.89) 1.28(0.74,2.21) 1.15(0.67,1.9
LDL-C <2/3 & GI ≥50% 1.16(0.75,1.80) 0.68(0.43,1.08) 0.65(0.41,1.0
LDL-C <2/3 & GI <50% 1 1 1
sdLDL-C ≥2/3 & GI ≥50% 2.05(1.26,3.33)† 1.70(1.02,2.82)* 1.63(1.00,2.6
sdLDL-C ≥2/3 & GI <50% 1.20(0.68,2.13) 0.79(0.51,1.23) 1.34(0.76,2.3
sdLDL-C <2/3 & GI ≥50% 1.12(0.72,1.73) 1.11(0.64,1.93) 0.87(0.56,1.3
sdLDL-C <2/3 & GI <50% 1 1 1
p-value: *<0.05, †<0.01, ‡<0.001.
All models were after adjusting for age, male gender, BMI, hypertension, alcohol drink
Levels of LDL-C (130 mg/dL) and sdLDL-C (37 mg/dL) were set at cut point of ≥ uppIt is well known that diabetes is a complicated disease
that involves different levels of cellular dysfunction and
multiple organs; hyperglycemia accelerated arterial stiff-
ening by increasing the formation of AGE, which alters
vessel wall structure and function. The irreversible for-
mation and deposition of reactive AGE may most likely
be the pathway involved in the pathogenesis of acceler-
ated atherosclerosis in patients with diabetes [32]. The
atherogenic effects of both fasting and postprandial
hyperglycemia were ascribed to glucose-mediated cellu-
lar properties via several mechanisms such as an in-
crease in nonenzymatic glycation of proteins and lipids.
The findings of this study enhanced our previous work
that postchallenge hyperglycemia is associated with the
subclinical atherosclerotic marker cardio-ankle vascular
index of arterial stiffness [24]. In another study involving
582 individuals aged 40–70 years and at risk for type 2
diabetes, postchallenge plasma glucose levels (30, 60, 90,
and 120 min) as well as GluAUC were more stronglyaction between atherogenic lipids and glycemic indices
0 Glucose 90 Glucose 120 Glucose AUC HbA1C
5)† 1.85(1.12,3.06)† 2.21(1.34,3.65)† 2.27(1.38,3.74)† 2.50(1.49,4.19)‡
7) 1.55(0.90,2.65) 1.78(1.04,3.04)* 1.40(0.81,2.41) 1.89(1.13,3.16)*
2) 0.71(0.45,1.12) 0.98(0.63,1.54) 0.84(0.53,1.32) 1.18(0.76,1.85)
1 1 1 1
6)* 1.47(0.91,2.40) 1.74(1.06,2.84)* 1.84(1.12,3.02)† 1.97(1.18,3.29)†
5) 1.25(0.70,2.21) 1.38(0.79,2.41) 1.10(0.62,1.94) 1.50(0.89,2.54)
6) 0.71(0.46,1.12) 0.99(0.64,1.54) 0.88(0.56,1.38) 1.21(0.78,1.88)
1 1 1 1
ing and current smoker, in addition to glycemic indices and LDL-C (or sdLDL-C).
er tertile (2/3) (66.7th percentile) in the models.
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cose and HbA1c levels [28]. However, applying inter-
action analyses to test the concurrent atherogenic lipids
and glycemic indices provides a deeper view of the inter-
action between lipids and hyperglycemia on the develop-
ment of atherosclerosis.
Studies from other Asian populations have demon-
strated that postchallenge glucose levels may be related
to CVD events in patients without diabetes [33,34].
Combining the additive effects atherogenesis observed
during the hyperglycemic state of the present study also
showed a higher prevalence of cardiovascular risk factors
among patients belonging to the highest tertile. It is rea-
sonable to assume that the postchallenge hyperglycemic
spikes may account for the aforementioned increased
CVD events. Therefore, postchallenge hyperglycemia
should be emphasized as a target for decreasing the inci-
dence of diabetes and CVD [35].
Recently, a research conducted in a type 2 diabetes
and prediabetes population has successfully displayed
the relationship between sdLDL with carotid IMT and
insulin resistance [36]. In addition to the traditional risk
markers, sdLDL has become an independent risk marker
for adverse metabolic status such as dysglycemia, indicat-
ing that more attention should be paid to hyperglycemia
which occurs independently from fasting, postchallenge,
or postprandial in subjects with atherogenic dyslipidemia
and particularly high levels of LDL-C or sdLDL-C to serve
as a primary prevention of CVD.
The present study should be interpreted in consider-
ation of some limitations. First, the study conducted
within non-diabetes patients instead of diabetes patients.
However, in order to eliminate confounding factors such
as chronic diabetes-related complications and interven-
tions, our study evaluated information gathered from
adults without diabetes. Second, even though HbA1c
was not statistically and significantly associated with
baPWV in the presented study, based on this cross-
sectional study, we cannot definitely make the conclu-
sion that postprandial hyperglycemia are more important
than HbA1C in the association with cardiovascular dis-
eases. Last, the exact mechanisms of interactions between
glucose and lipids profiles need to be elucidated in future
study.Conclusions
In conclusion, significant interactions between LDL sub-
class particles and different glycemic indices displayed an
additive effect between these two risk factors on arterial
stiffness. In addition, only concurrent highest tertile levels
of both glycemic indices and atherogenic LDL-C or
sdLDL-C have significant risk for arterial stiffness in non-
diabetic adults.Methods
From 2009 to 2011, we recruited 592 middle-aged (age
range, 20–60 years old) adults without clinical diabetes
(fasting plasma glucose <7.0 mmol/L or 2-h plasma glu-
cose <11.1 mmol/L after OGTT) or known history of
CHD or stroke to participate as the control group of
“Work-related factors and cardiovascular events in pa-
tients with coronary heart disease” study conducted in
the National Taiwan University Hospital, Taipei, Taiwan
[37]. The present study of below diagnostic OGTT dia-
betes criteria was defined as 2-h glucose ≥11.1 mmol/L
after OGTT but without previously known clinical dia-
betes as above mentioned. Informed consent was ob-
tained prior to participation. The body mass index was
calculated by the formula: weight (kg)/[height (m)]2.
Smoking habit was defined as persons who had smoked
more than 100 cigarettes in their lifetimes and still
smoke at the time of the study. Hypertension is defined
as SBP values >140 mmHg and/or DBP >90 mmHg, al-
cohol consumption. The alcohol consumption was de-
fined as up to 1 drink per day for women and up to 2
drinks per day for men. This study was approved by the
ethics committee of National Taiwan University Hospital.
Blood sampling for lipids and biochemical studies
Following overnight fasting for 10–14 h, the subjects
underwent a standard 75-g oral OGTT to evaluate their
response to glucose loading. A venous blood sample was
obtained through the antecubital vein before OGTT and
at 30, 60, 90, and 120 min after OGTT. The glucose area
under curve (GluAUC) for each subject was calculated
by the five times (0, 30, 60, 90, and 120) of the blood
glucose level sample after OGTT. The postprandial
period was defined to extend until 120 min after meal
onset, baseline (0) was defined as the pre-meal plasma
value. The assessment of levels of lipids, including chol-
esterol, triglycerides, HDL-C, and LDL-C, Cholesterol
within small dense LDL (15.0 nm-20.0 nm) was mea-
sured as described previously [38,39] using a newly devel-
oped automated homogeneous assay (Denka Seiken Co.,
Ltd., 3-4-2 Nihonbashi-Kayabacho, Chuo-Ku, Tokyo) and
analyzed on an autoanalyzer (Toshiba FR-200 automatic
chemistry analyzer, Tokyo, Japan). Subject’s blood samples
were collected in the morning under 10–14 h fasting con-
ditions, after which the blood sample were centrifuged for
10 min at 3,000 revolutions per minute. The serum was
separated and stored at −80°C. The blood collection to
separation process did not exceed 3 hours under proper
laboratory protocol.
Brachial-ankle pulse wave velocity measurements
The brachial-ankle pulse wave velocity (baPWV) was
measured in the morning after participants received
OGTT using a noninvasive vascular screening device
Ding et al. Lipids in Health and Disease 2014, 13:179 Page 7 of 8
http://www.lipidworld.com/content/13/1/179(Colin VP-1000; Colin Co., Ltd., Komaki, Japan). This
device simultaneously recorded the baPWV, electrocar-
diogram, and arterial blood pressure from all four limbs
(at both the left and right brachia and ankles) and calcu-
lated the ankle-brachial index. Subjects were examined
in the supine position. Electrodes were placed on both
wrists to obtain an electrocardiogram. The cuffs were
connected to a sensor that measured the volume pulse
form and an oscillometric pressure sensor that measured
blood pressure. The time interval between the wave
front of the brachial waveform and the ankle waveform
was defined as the pulse transit time between the bra-
chia and the ankle (ΔTba). The distance between the
arm and ankle was estimated automatically according to
the subject’s height. The distance from the heart to the
brachia (Db) was measured using the following equation:
Db = 0.2195 × height of the patient (cm) −2.0734. The
distance from the heart to the ankle (Da) was measured
using the following equation: Da = 0.8129 × height of the
patient (cm) +12.328. The baPWV was calculated using
the following equation: baPWV = (Da −Db)/ΔTba. The
validity and reproducibility of baPWV measurements
has been reported elsewhere [20,21].
Statistical analysis
Data analysis was performed using Statistical Analysis
System (SAS) software (version 9.2, SAS Institute Inc,
Cary NC, USA). The statistical significance level was set
at 0.05, and the power calculation was set with a 1-beta
value of 80% for this study. Continuous variables were
expressed as means ± standard deviations and categorical
data was expressed by percentage. The statistical methods
used to test the significance of the compare continuous
variables (Tables 1 and 2) were performed with CA
(Cochran-Armitage) test for trend.
Basic information of cardiovascular characteristics and
subclinical atherosclerotic markers was compared by
Chi-square test for trend across the tertile distribution
of the groups using glucose levels during postchallenge
hyperglycemic spikes 1 h after the OGTT, which was
performed to demonstrate postchallenge hyperglycemic
status. The trend differences between the cardiovascular
characteristics of the patients across the tertile distribu-
tions of the groups for baPWV were also evaluated.
The effects of LDL-C (or sdLDL-C) and glucose levels
at the different time points of OGTT results were mea-
sured using multiple logistic regression models to esti-
mate the odds ratios and 95% confidence intervals for
arterial stiffness in terms of baPWV at the level of ≥75th
percentile. This analysis was performed after controlling
for related covariates, including age, gender, BMI, hyper-
tension, smoking, and alcohol consumption. Since there
were high correlations observed between the different
glycemic indices and atherogenic LDL-C (or sdLDL-C),the concurrent presence of these two components was
treated as interaction to test their risk for arterial
stiffness.
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